Teva Pharmaceutial Industries (NYSE: TEVA) is a dirt-cheap pharma stock. The company's shares are trading at a rock-bottom price-to-sales ratio of 0.88. That's a cut-rate valuation for any large cap pharma play, especially for one with a well-established global footprint like Teva. Nevertheless, this deeply discounted drugmaker has still failed to attract bargain hunters this year.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,